Cargando…
Idelalisib: a rare cause of enterocolitis
Idelalisib is an oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, approved by FDA since July 2014 for the treatment of relapsed follicular B-cell non-Hodgkin lymphoma. Data from three phases of the study involving idelalisib demonstrate diarrhea (47%) to be the common adverse effect. The...
Autores principales: | Balagoni, Harika, Chaudhari, Dhara, Reddy, Chakradhar, Young, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805750/ https://www.ncbi.nlm.nih.gov/pubmed/27065742 http://dx.doi.org/10.20524/aog.2016.0022 |
Ejemplares similares
-
Obstructive Jaundice as an Initial Manifestation of Non-Hodgkin Lymphoma: Treatment Dilemma and High Mortality
por: Chaudhari, Dhara, et al.
Publicado: (2013) -
Rapid and complete response to idelalisib in a case of Richter syndrome
por: Bagacean, Cristina, et al.
Publicado: (2019) -
Autoimmune Pancreatitis Type 2: Case Report
por: Onweni, Chidinma, et al.
Publicado: (2017) -
Fatal Neutropenic Enterocolitis Caused by Stenotrophomonas maltophilia: A Rare and Underrecognized Entity
por: Kaito, Satoshi, et al.
Publicado: (2018) -
Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease
por: Uday, R. V. Sriram, et al.
Publicado: (2021)